Bruce Klugherz, MD
Cardiovascular Disease · Horsham, PANPI 1417941915
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $247,492 of the $290,790 with a category attached, or 85.1%. It is spread thinly across 43 manufacturers, the largest accounting for just 22.7%. 2025 is the largest year on record at $65,314, 2.7 times the $23,953 reported in 2019. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 773 payments — averaging $376.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$66K
- Boehringer Ingelheim$62K
- Novo Nordisk$56K
- Merck$26K
- Lilly USA, LLC$17K
- Pfizer$11K
- plus $54K from 37 others
Across 15 payments — averaging $56,372 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$301K
- Amgen$266K
- AstraZeneca$149K
- Astrazeneca UK Limited$129K
What the payments were for
- Consulting fees$3,7501%
- Speaking & faculty fees$247,49285%
- Travel & lodging$17,4716%
- Food & beverage$22,0348%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$76,540
- XARELTO$65,066
- Ozempic$55,196
- VERQUVO$50,126
- ELIQUIS$17,058
- NEXLIZET$10,068
- NEXLETOL$10,068
- Watchman$6,763
- FARXIGA$5,288
- CoreValve Evolut$3,325
- ENTRESTO$2,750
- COREVALVE EVOLUT R$2,531
- Sundance$1,400
- FUROSCIX$1,200
- CT Equip Undiv$950
- WATCHMAN Access System$509
- INTERVENTIONAL ANGIOGRAPHY SYSTEM$484
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$481
- Acute cardiovascular care$300
- SAPIEN 3 Ultra RESILIA$271
How this compares
$290,790 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 50 | $1,190,792 |
| EliquisApixaban | 564 | $600,176 |
| XareltoRivaroxaban | 253 | $231,581 |
| EntrestoSacubitril/Valsartan | 204 | $213,918 |
| JardianceEmpagliflozin | 105 | $108,579 |
| Repatha SureclickEvolocumab | 110 | $93,432 |
| MultaqDronedarone Hcl | 48 | $51,958 |
| FarxigaDapagliflozin Propanediol | 46 | $35,037 |
| BrilintaTicagrelor | 41 | $26,072 |
| VerquvoVericiguat | 19 | $25,611 |
| NexletolBempedoic Acid | 28 | $22,344 |
| Metoprolol Succinate | 990 | $15,742 |
| Praluent PenAlirocumab | 18 | $14,162 |
| Atorvastatin Calcium | 756 | $10,746 |
| Ranolazine ErRanolazine | 102 | $9,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $11,083 | $1,790,968614 claims |
| Johnson & JohnsonXarelto | $66,050 | $231,581253 claims |
| NovartisEntresto | $3,435 | $213,918204 claims |
| Boehringer IngelheimJardiance, Pradaxa | $61,617 | $114,879119 claims |
| AstraZenecaFarxiga, Brilinta | $6,128 | $61,11087 claims |
| Sanofi-aventis U.S. LLCMultaq | $239 | $51,95848 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $10,068 | $31,77843 claims |
| MerckVerquvo | $25,903 | $25,61119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Horsham
- Adam CohenHorsham$185K
- Hemal GadaWormleysburg$1.8M
- Benjamin KalsmithPgh$1.7M
- Peter KoweyWynnewood$1.5M
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Rhian DaviesYork$853K
- Sarang MangalmurtiBryn Mawr$728K
- Sabahat BokhariAllentown$578K
- George GabrielPittsburgh$563K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.